Q-omics provides the consensus-scored ETF1P1 profile across patient tissues and cancer cell-line models. ETF1P1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ETF1P1 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, ETF1P1 RNA expression shows 15,137 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, LIHC, and UVM as cancer lineages where ETF1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ETF1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ETF1P1 survival associations across molecular data types. ETF1P1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ETF1P1 RNA expression–survival associations across cancer types. High ETF1P1 expression shows unfavorable associations in ACC and LUSC, but favorable associations in BLCA, READ, KIRP and LAML. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ETF1P1 RNA expression.
This table summarizes ETF1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ETF1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ETF1P1 shows lower tumor expression in ESCA and higher tumor expression in LIHC, KIRC, STAD and COAD. The LIHC box plot shows higher ETF1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.068, t-test p = .004).
This table shows molecular features associated with ETF1P1 in patient tissues and cancer cell lines. In patient samples, ETF1P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
